ROUNDUP/Aktien Europa Schluss: Kleines Minus – US-Teuerung brings keine Impulse | 10.10.24

PARIS/LONDON/ZURICH (dpa-AFX) – Europas Aktienmärkte has a moderate nighttime in the Donnerstag. The Spannung erwarteten Verbraucherpreise from the USA did not bring any new impetus. When the US government had a bigger response, inflation was higher in September if forecasts had fallen.

Der Eurozonen-Leitindex EuroStoxx 50 verlor 0.25 Prozent auf 4,970.34 Punkte. Außerhalb des Euroraumes gab der Schweizerische SMI a 0.37 Prozent auf 12,077.76 Punkte nach. The British FTSE 100 lost 0.07 Prozent auf 8,237.73 Zähler.

“It was so high that the inflation rates in the United States were measured in the United States,” said analyst Konstantin Oldenburger of CMC Markets. “Larger investments can be made, while the US-Notenbank Fed figures have been adopted by the Kurs, the Zinsen ‘schrittweise’ will no longer be shortened.” The big story sees the strong US economy and inflation when there is no longer any inflation. Everything in general is that the Teuerung has gone by the Zwei-Prozent-Ziel of the Fed, and “das ist, was zählt.”

Stärkster Sektor war in de Versicherungsbranche. If Hurrikan “Milton” is one of the West Coast Florida’s abgeschwächt hat, he provides relief and the Aktien of the European Rückversichere Auftrieb gets to work. Im EuroStoxx winnowed Munich Re als Spitzenwert 2.9 Prozent. Scores rose in Paris by 2.8 Prozent and in SMI Swiss Re Favorit rose by plus 2.8 Prozent.

Among pharmaceutical companies, the British GSK companies (GlaxoSmithKline) are up with more than 3.2 percent. Foreign countries in the United States have made a millennium profit in the form of a loan with a longer credit risk of the medicine Zantac beigelegt. A number of companies have emerged with Klägerfirma’s disease, which 93 percent – approximately 80,000 – at Staatsgerichten anhängigen produkthaftungsklagen roads Zantac (Ranitidin) vertreten. Analysts are positive.

Among the Chemiewerten, the Aktien des Schweizer Riechstoff- and Aromenherstellers Givaudan 0.4 Prozent. The Umsatzentwicklung by Quartal has been brilliant, by ZKB analyst Daniel Bürki. If the Wachstum is “stunning”, it is possible to do this. Baader Bank analyst Konstantin Wiechert has stated that the bank’s financial position is still moderate.